Imunon, Inc. (IMNN) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. I will be your conference operator for today. At this time, I would like to welcome everyone to the Immunon Second Quarter 2026 Financial Results and Business Update Conference Call. I will now turn the call over to Wouter Pinto, Managing Director of Investor Relations at KCSA Strategic Communications, for introductions. Please go ahead. Thank you, operator, and good morning. Welcome to the MUNON second quarter 2026 Financial Results and Business Update conference call. Joining us today are Stacy Lindborg, president and chief executive officer, Dr. Douglas Faller, chief medical officer, and Josh Blacher, chief financial officer. Michael Tardugno, the company's executive chairman, is also on the line for the Q&A portion of today's call. Before we begin, I'd like to remind everyone that our remarks today include forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include, but are not limited to, statements regarding the timing and enrollment of the company's clinical trials, the potential of the company's therapies to address unmet medical needs, the market potential for its product candidates, if approved, and the company's plans and expectations for its development programs. Words such as may, will, expect, plan, anticipate, estimate, and intend identify these forward-looking statements and actual results may differ materially from those projected. Digital information on the factors that could cause actual results to differ is detailed in Immunon's Filings, Mysteries, and Exchange Commission, which are available at sec.gov and on the company's website. Overlooking statements made on the call speak only as of today's date, and the company undertakes no ob...